Ginkgo Bioworks Q3 2026 Earnings Call Transcript Unavailable; Hold Thesis Unchanged Based on Q2 2025 Filings

What happened

Ginkgo Bioworks held its Q3 2026 earnings call, but the transcript content was not provided in the news context. Based on the latest available filings through Q2 2025, the company was executing a restructuring and shifting to fee-for-service while consolidating into Biofab1. As of June 30, 2025, cash and restricted cash totaled $251.4 million, with negative free cash flow around $40 million per quarter. Management's publicly stated target of adjusted EBITDA breakeven by end-2026 remains unconfirmed. Without the earnings call details, the DeepValue master report's HOLD rating remains in force.

Implication

Investors should remain cautious given the company's ongoing cash burn and potential dilution, though net debt is low. The pivot to fee-for-service may improve unit economics, but near-term revenue remains modest with Biosecurity still pressured. Positive catalysts include high-profile partnerships with Merck, Boehringer, and DARPA, but execution risk is high. The lack of Q3 2026 earnings call content prevents updating the thesis; the DeepValue hold rating is maintained. Key metrics to track are quarterly cash outflow, Cell Engineering revenue growth, and progress toward adjusted EBITDA breakeven.

Thesis delta

No shift in thesis. The hold rating is maintained based on the latest filings through Q2 2025 showing restructuring progress but liquidity concerns. Without the Q3 2026 earnings call transcript, we cannot assess any changes; the thesis remains contingent on cash preservation and breakeven execution.